Bone and Soft‐Tissue Sarcoma Risk in Long‐Term Survivors of Hereditary Retinoblastoma Treated With Radiation

PURPOSE Survivors of hereditary retinoblastoma have excellent survival but substantially increased risks of subsequent bone and soft-tissue sarcomas, particularly after radiotherapy. Comprehensive investigation of sarcoma risk patterns would inform clinical surveillance for survivors. PATIENTS AND METHODS In a cohort of 952 irradiated survivors of hereditary retinoblastoma who were originally diagnosed during 1914 to 2006, we quantified sarcoma risk with standardized incidence ratios (SIRs) and cumulative incidence analyses. We conducted analyses separately for bone and soft-tissue sarcomas occurring in the head and neck (in/near the radiotherapy field) versus body and extremities (out of field). RESULTS Of 105 bone and 124 soft-tissue sarcomas, more than one half occurred in the head and neck (bone, 53.3%; soft tissue, 51.6%), one quarter in the body and extremities (bone, 29.5%; soft tissue, 25.0%), and approximately one fifth in unknown/unspecified locations (bone, 17.1%; soft tissue, 23.4%). We noted substantially higher risks compared with the general population for head and neck versus body and extremity tumors for both bone (SIR, 2,213; 95% CI, 1,671 to 2,873 v SIR, 169; 95% CI, 115 to 239) and soft-tissue sarcomas (SIR, 542; 95% CI, 418 to 692 v SIR, 45.7; 95% CI, 31.1 to 64.9). Head and neck bone and soft-tissue sarcomas were diagnosed beginning in early childhood and continued well into adulthood, reaching a 60-year cumulative incidence of 6.8% (95% CI, 5.0% to 8.7%) and 9.3% (95% CI, 7.0% to 11.7%), respectively. In contrast, body and extremity bone sarcoma incidence flattened after adolescence (3.5%; 95% CI, 2.3% to 4.8%), whereas body and extremity soft-tissue sarcoma incidence was rare until age 30, when incidence rose steeply (60-year cumulative incidence, 6.6%; 95% CI, 4.1% to 9.2%), particularly for females (9.4%; 95% CI, 5.1% to 13.8%). CONCLUSION Strikingly elevated bone and soft-tissue sarcoma risks differ by age, location, and sex, highlighting important contributions of both radiotherapy and genetic susceptibility. These data provide guidance for the development of a risk-based screening protocol that focuses on the highest sarcoma risks by age, location, and sex.

[1]  M. Tucker,et al.  Patterns of Cause-Specific Mortality Among 2053 Survivors of Retinoblastoma, 1914-2016. , 2019, Journal of the National Cancer Institute.

[2]  H. Brisse,et al.  Correlation between RB1germline mutations and second primary malignancies in hereditary retinoblastoma patients treated with external beam radiotherapy. , 2019, European journal of medical genetics.

[3]  C. Ronckers,et al.  Risk of Subsequent Bone Cancers Among 69 460 Five-Year Survivors of Childhood and Adolescent Cancer in Europe , 2018, Journal of the National Cancer Institute.

[4]  C. Ronckers,et al.  Risk of Soft-Tissue Sarcoma Among 69 460 Five-Year Survivors of Childhood Cancer in Europe , 2017, Journal of the National Cancer Institute.

[5]  David M. Thomas,et al.  Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis , 2017, JAMA oncology.

[6]  Steven J. M. Jones,et al.  Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas , 2017, Cell.

[7]  L. Mirabello,et al.  Germline and somatic genetics of osteosarcoma — connecting aetiology, biology and therapy , 2017, Nature Reviews Endocrinology.

[8]  K. Jöckel,et al.  Incidence of second cancers after radiotherapy and systemic chemotherapy in heritable retinoblastoma survivors: A report from the German reference center , 2017, Pediatric blood & cancer.

[9]  S. Brodie,et al.  Intra-Arterial Chemotherapy (Ophthalmic Artery Chemosurgery) for Group D Retinoblastoma , 2014, PloS one.

[10]  Shigenobu Suzuki,et al.  Second primary osteosarcomas in patients with retinoblastoma. , 2015, Japanese journal of clinical oncology.

[11]  C. Shields,et al.  Treatment of Retinoblastoma in 2015: Agreement and Disagreement. , 2015, JAMA ophthalmology.

[12]  M. Tucker,et al.  Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  E. Lis,et al.  Whole‐body magnetic resonance imaging (WB‐MRI) as surveillance for subsequent malignancies in survivors of hereditary retinoblastoma: A pilot study , 2014, Pediatric blood & cancer.

[14]  H. Meijers-Heijboer,et al.  RB1 mutation spectrum in a comprehensive nationwide cohort of retinoblastoma patients , 2014, Journal of Medical Genetics.

[15]  J. Benichou,et al.  Risk of second bone sarcoma following childhood cancer: role of radiation therapy treatment , 2014, Radiation and Environmental Biophysics.

[16]  G. Draper,et al.  Second and subsequent tumours among 1927 retinoblastoma patients diagnosed in Britain 1951–2004 , 2013, British Journal of Cancer.

[17]  P. Maeder,et al.  Second cranio-facial malignancies in hereditary retinoblastoma survivors previously treated with radiation therapy: clinic and radiologic characteristics and survival outcomes. , 2013, European journal of cancer.

[18]  P. Rajaraman,et al.  Risk factors associated with secondary sarcomas in childhood cancer survivors: a report from the childhood cancer survivor study. , 2012, International journal of radiation oncology, biology, physics.

[19]  J. Seddon,et al.  Increased risk of secondary uterine leiomyosarcoma in hereditary retinoblastoma. , 2012, Gynecologic oncology.

[20]  P. Rajaraman,et al.  Sarcoma risk after radiation exposure , 2012, Clinical Sarcoma Research.

[21]  M. Tucker,et al.  Sarcomas in hereditary retinoblastoma , 2012, Clinical Sarcoma Research.

[22]  C. Stiller,et al.  Long-term risks of subsequent primary neoplasms among survivors of childhood cancer. , 2011, JAMA.

[23]  J. Beyene,et al.  Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. , 2011, The Lancet. Oncology.

[24]  A. Moll,et al.  Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. , 2008, Journal of the National Cancer Institute.

[25]  M. Tucker,et al.  Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. , 2007, Journal of the National Cancer Institute.

[26]  R. Cozza,et al.  Mortality from second tumour among long-term survivors of retinoblastoma: a retrospective analysis of the Italian retinoblastoma registry , 2006, Oncogene.

[27]  Eva Steliarova-Foucher,et al.  International Classification of Childhood Cancer, third edition , 2005, Cancer.

[28]  D. Easton,et al.  Lifetime risks of common cancers among retinoblastoma survivors. , 2004, Journal of the National Cancer Institute.

[29]  M. Boers,et al.  Second primary tumors in hereditary retinoblastoma: a register-based study, 1945-1997: is there an age effect on radiation-related risk? , 2001, Ophthalmology.

[30]  L. Desjardins,et al.  Osteosarcoma following retinoblastoma: Age at onset and latency period , 2001, Ophthalmic genetics.

[31]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[32]  D. Abramson,et al.  Second nonocular tumors in survivors of bilateral retinoblastoma: a possible age effect on radiation-related risk. , 1998, Ophthalmology.

[33]  J. Fraumeni,et al.  Cancer Incidence After Retinoblastoma: Radiation Dose and Sarcoma Risk , 1997 .

[34]  J. Fraumeni,et al.  Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. , 1997, JAMA.

[35]  E. Kramárová,et al.  The international classification of childhood cancer , 1996, International journal of cancer.

[36]  H. B. Marsden,et al.  Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. , 1996, Journal of the National Cancer Institute.

[37]  R. Ellsworth,et al.  Osteogenic sarcoma of the humerus after cobalt plaque treatment for retinoblastoma. , 1980, American journal of ophthalmology.

[38]  H. Stallard.  The treatment of retinoblastoma. , 1968, Bibliotheca ophthalmologica : supplementa ad ophthalmologica.